Latuda is a very favourable choice for bipolar depression
This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message
Sent On: Sat Mar 25 20:20:45 2023
1 selected item
Item 1-1 of 1 (Display the 1 citation in PubMed)
1. CNS Spectr. 2023 Mar 24:1-8. doi: 10.1017/S1092852923001190. Online ahead of print.
Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression.
Tocco M(1)(2), Newcomer JW(3)(4), Mao Y(1)(2), Pikalov A(1)(2).
Author information: (1)Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA. (2)Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. (3)Thriving Mind South Florida, Miami, FL, USA. (4)Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
OBJECTIVE: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality. This post hoc analysis assessed the effect of treatment with lurasidone on risk of MetS in patients with bipolar depression. METHODS: Data used in the current analyses consisted of 3 double-blind (DB), placebo-controlled, 6-week studies in adults with bipolar I depression (N = 1192), consisting of 1 monotherapy, and 2 adjunctive trials (lithium or valproate). Also analyzed was a 6-month open-label (OL) extension study (monotherapy, N = 316; adjunctive therapy, N = 497); and a 5-month, OL, stabilization phase followed by randomization to a 28-week DB, placebo-controlled, adjunctive therapy study with lurasidone (N = 490). MetS was defined based on NCEP ATP III criteria (2005 revision). RESULTS: The proportion of patients with new-onset MetS was similar for lurasidone vs placebo in the short-term studies (monotherapy, 13.9% vs 15.3%; adjunctive therapy, 13.6% vs 11.0%); and remained stable during both the 6-month extension phase study (monotherapy, 15.2%; adjunctive therapy, 16.9%), and the 5-month stabilization study (adjunctive therapy, 12.2%). After 28 weeks of DB treatment (following 5-month treatment in the stabilization study), new onset MetS was observed at endpoint (OC) in 26.2% of the lurasidone group, and 30.8% of the placebo group. CONCLUSIONS: This post hoc analysis found that both short and long-term treatment with lurasidone was associated with a relatively low risk for the development of MetS in patients with bipolar I disorder. These findings are consistent with similar analyses in patients with schizophrenia.
DOI: 10.1017/S1092852923001190 PMID: 36961124